← Oncology Approval Tracker

FDA DECISION ·

Vonjo

pacritinib · CTI BioPharma

Accelerated approvalNew therapyMyelofibrosis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with intermediate- or high-risk primary myelofibrosis, or myelofibrosis following polycythemia vera or essential thrombocythemia, and platelet counts below 50 × 10⁹/L.

LAMPGEN ANALYSIS

Why it matters

The platelet threshold targets a population with severe thrombocytopenia and limited options.

What research teams should watch

Verify disease risk, a contemporaneous platelet count, and bleeding risk when documenting eligibility.

PRIMARY RECORDS

Sources